Postpartum weight is one of the most common reasons people ask about semaglutide and tirzepatide, and many of them are still nursing. The labels do not give a flat yes or no. They also treat the tablet and the injection differently.
This page sets out what each label’s lactation section says, what has been measured in human milk, and where the evidence stops. It is general information, not medical advice for your situation.
What the four labels say
Every label for these drugs has a section 8.2 on lactation, and all four carry the same balancing sentence. The benefits of breastfeeding “should be considered along with the mother’s clinical need” for the drug and any potential adverse effects on the infant [1].
| Label | Human milk data in the label | What the label says about breastfeeding |
|---|---|---|
| Ozempic injection | None. In rats, milk levels were 3 to 12 times lower than in maternal plasma | Weigh the benefits of breastfeeding against the mother's need and possible infant effects |
| Wegovy injection | None for injected semaglutide | Same weighing; the label notes the injection does not contain the tablet's absorption enhancer |
| Wegovy tablets | Semaglutide below the lower limit of quantification; the enhancer and its metabolites present | Breastfeeding is not recommended during treatment |
| Zepbound and Mounjaro | One single-dose study: 164 of 171 samples undetectable in 11 women | Same weighing; no data on infant effects or milk production |
The Ozempic label states there are “no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production” [1]. It adds that the rat finding may not carry over, because lactation differs between species.
Why the tablet is different
Wegovy tablets contain salcaprozate sodium (SNAC), which the label calls an absorption enhancer. The Wegovy label reports a clinical lactation study of the tablet [2].
Semaglutide itself was below the lower limit of quantification in milk. “However, SNAC and/or its metabolites are present in human milk,” the label states.
Infants may clear SNAC more slowly than adults, so it could build up. Because of that unknown risk, and because injected forms without SNAC exist, the label says to advise patients that breastfeeding is not recommended on Wegovy tablets.
LactMed, the federal database on drugs in breastfeeding, makes the same split for semaglutide overall [5]. It says “only injectable forms of semaglutide should be used during breastfeeding.” The tablet itself is covered in the Wegovy pill.
What was measured for semaglutide
One published study has measured semaglutide in human milk. It used samples from eight women injecting it, collected at 0, 12 and 24 hours after a dose [7].
“Semaglutide was not detected in any of the collected human milk samples,” the authors report. Their method could detect 1.7 ng/mL.
They then assumed a worst case, in which milk held drug at the quantification limit. The highest relative infant dose they projected was 1.26%, against a commonly used 10% threshold.
LactMed adds the doses and the infants [5]. The mothers used 0.25 to 1 mg weekly, and their infants were 4 to 23 months old and fed a mix of milk and other food.
The infants received breast milk for 3 to 9 weeks while their mothers took semaglutide. “All of the infants were reported to have normal growth and development by their mothers,” LactMed records.
What was measured for tirzepatide
The tirzepatide labels report a study in 11 healthy lactating women, each given a single 5 mg injection [3]. Milk was sampled for 28 days afterward.
Tirzepatide was undetectable in 164 of 171 samples, with a detection limit of 4 ng/mL. The drug found in the other seven samples added up to “less than 0.02% of the maternal administered dose.”
The Mounjaro label carries the same study in the same words [4]. Both say there are no data on effects in the breastfed infant or on milk production.
LactMed flags the design’s limit [6]. A single dose “does not account for accumulation that would occur during typical use,” so levels at steady state are probably higher.
It also reports an unpublished study of five women on 2.5 to 5 mg a week. No sample exceeded the quantification limit of 2.38 mcg/L, and none of the mothers reported infant effects attributed to the drug.
LactMed’s summary is that if a mother requires tirzepatide, “it is not a reason to discontinue breastfeeding.” It still advises caution, especially with a newborn or preterm infant.
Why so little reaches the infant
These are large peptide molecules. LactMed notes that tirzepatide is “probably partially destroyed in the infant’s gastrointestinal tract and poorly absorbed orally” [6].
For semaglutide, it notes that oral bioavailability in adults peaks at 1% [5]. That figure is for adults; infant absorption has not been measured.
Liraglutide, an older drug in the same class, has no milk data at all. LactMed advises caution with it for that reason [10].
Why the advice you hear conflicts
The labels and LactMed describe a risk-benefit decision. Other sources are stricter, and the evidence behind either stance is thin.
A 2026 international consensus review opens by stating that pregnancy on these drugs is contraindicated, “as is breastfeeding” [9]. Of the 34 studies it found, one addressed lactation.
A 2026 systematic review of diabetes drugs in breastfeeding found milk-transfer data for only 5 of 20 drugs, semaglutide among them [8].
It found that 78% of guideline recommendations were against using these drugs while breastfeeding. Only 4.4% of recommendations rested on clinical evidence.
So a prescriber reading one guideline may say no, and another reading LactMed may say yes. Both are working from a handful of mothers.
What nobody has measured yet
No study has measured milk at 2.4 mg of semaglutide or at tirzepatide doses above 5 mg. No study has followed exposed infants beyond a few weeks.
No label reports data on milk supply. The Wegovy label says semaglutide decreases calorie intake, likely by affecting appetite [2].
LactMed notes that some experts recommend closely monitoring infant growth and milestones, and the nutritional status of the nursing mother [6].
Pregnancy itself, including the 2-month washout the labels ask for before a planned pregnancy, is covered in Ozempic and pregnancy. The pill interaction that matters after delivery is in tirzepatide and birth control.
What tends to happen to weight when treatment pauses is in what happens when you stop taking semaglutide. The wider side-effect record is in semaglutide side effects, and options are compared on the weight-loss peptide rankings.